The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

The present invention provides methods for improving or accelerating wound healing in a subject comprising administering to a wound of the subject in need thereof an agent that suppresses expression of a clock gene, wherein the clock gene is neuronal PAS domain protein 2 (Npas2). This invention also relates to methods for regenerating alveolar bone, regenerating connective tissue at a wound site, and for decreasing wound area size comprising administering to a bone loss site or a wound site, in particular, an open wound site, of a subject an agent that suppresses expression of Npas2.

The present invention provides methods for improving or accelerating wound healing in a subject comprising administering to a wound of the subject in need thereof an agent that suppresses expression of a clock gene, wherein the clock gene is neuronal PAS domain protein 2 (Npas2). This invention also relates to methods for regenerating alveolar bone, regenerating connective tissue at a wound site, and for decreasing wound area size comprising administering to a bone loss site or a wound site, in particular, an open wound site, of a subject an agent that suppresses expression of Npas2.

The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

The invention provides methods, compositions, and medical kits for treating cancer using combination therapy including a BRAF and/or MEK inhibitor and at least one additional therapeutic agent that inhibits at least one target impacting oxidation state of the cancer.

The invention provides methods, compositions, and medical kits for treating cancer using combination therapy including a BRAF and/or MEK inhibitor and at least one additional therapeutic agent that inhibits at least one target impacting oxidation state of the cancer.

A method of reducing tooth-associated pain includes at least shaping plug product into a shape, identifying a source of tooth-associated pain, and engaging the shaped plug product directly with the source of tooth-associated pain. Some implementations include at least shaping a plug product that is at least partly composed of gum base. Some particular implementations include at least shaping a plug product that is completely composed of gum base. Some other particular implementations include at least shaping a plug product that includes one or more numbing agents. Some alternative implementations, include at least shaping a plug product that is at least partly composed of beeswax. A plug product for reducing tooth-associated pain includes a mixture that includes at least one or more numbing agents, at least one of beeswax or gum base and at least one of stevia, corn starch, glycerin, citric acid, or corn syrup.

A method of reducing tooth-associated pain includes at least shaping plug product into a shape, identifying a source of tooth-associated pain, and engaging the shaped plug product directly with the source of tooth-associated pain. Some implementations include at least shaping a plug product that is at least partly composed of gum base. Some particular implementations include at least shaping a plug product that is completely composed of gum base. Some other particular implementations include at least shaping a plug product that includes one or more numbing agents. Some alternative implementations, include at least shaping a plug product that is at least partly composed of beeswax. A plug product for reducing tooth-associated pain includes a mixture that includes at least one or more numbing agents, at least one of beeswax or gum base and at least one of stevia, corn starch, glycerin, citric acid, or corn syrup.

Provided are a compound as a PD-L1 inhibitor, a preparation method therefor, and use thereof. Further provided is use of the compound or a pharmaceutical composition thereof in the preparation of a medicine, wherein the medicine is used for preventing and treating a PD-L1-related disease.